LEADER 03121nam  2200661 a 450 
001 9910810609003321
005 20200520144314.0
010   $a1-281-72653-2
010   $a9786611726539
010   $a0-9802094-7-1
035   $a(CKB)1000000000755328
035   $a(EBL)3340016
035   $a(SSID)ssj0000179479
035   $a(PQKBManifestationID)11168949
035   $a(PQKBTitleCode)TC0000179479
035   $a(PQKBWorkID)10149247
035   $a(PQKB)11350232
035   $a(MiAaPQ)EBC3340016
035   $a(Au-PeEL)EBL3340016
035   $a(CaPaEBR)ebr10233893
035   $a(CaONFJC)MIL172653
035   $a(OCoLC)923251603
035   $a(EXLCZ)991000000000755328
100   $a20080305d2008      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aInnovation and the pharmaceutical industry $ecritical reflections on the virtues of profit /$fedited by H. Tristram Engelhardt Jr. and Jeremy R. Garrett
210   $aSalem, MA $cM & M Scrivener Press$dc2008
215   $a1 online resource (253 p.)
225 1 $aTrends and conflicts
300   $aDescription based upon print version of record.
311   $a0-9802094-4-7 
320   $aIncludes bibliographical references and index.
327   $aPharmaceutical innovation and the market: the pursuit of profit and the amelioration of the human condition / H. Tristram Engelhardt Jr. & Jeremy R. Garrett -- The unavoidable goodness of profit: the cunning of reason and the realization of human well-being / H. Tristram Engelhardt Jr -- Corporate social responsibility and business ethics in the pharmaceutical industry / Nicholas Capaldi -- Pharmaceutical companies: psychopaths or scapegoats / Pepe Lee Chang -- Autonomy, constraining options, and pharmaceutical costs / James Stacy Taylor -- Pharmaceutical advertising and patient autonomy / Andrew I. Cohen -- Does America have a second drug problem? / Richard A. Epstein -- Global drug innovation in a world of financial finitude: retailing virtue to promote -- Capital formation and profit / Michael A. Rie -- Time, money, and the market for drugs / John C. Goodman -- Perils of parallel trade: reimporting prescription drugs from Canada to the U.S. / John R. Graham -- Risk, responsibility, and litigation / Sandra H. Johnson & Ana Smith Iltis.
410  0$aConflicts and trends.
606   $aPharmaceutical industry
606   $aDrug development
606   $aMedical innovations
606   $aMedical policy$zUnited States
606   $aDrugs$xeconomics$zUnited States
615  0$aPharmaceutical industry.
615  0$aDrug development.
615  0$aMedical innovations.
615  0$aMedical policy
615  0$aDrugs$xeconomics
676   $a338.4/791510973
701   $aEngelhardt$b H. Tristram$g(Hugo Tristram),$f1941-$046590
701   $aGarrett$b Jeremy R$01690825
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910810609003321
996   $aInnovation and the pharmaceutical industry$94107317
997   $aUNINA